Clinical trial tests new schedule of radiation therapy for recurring prostate cancer

Xenograft Model of Prostate Cancer

Xenograft Model of Prostate Cancer
Source: NCI Visuals Online

Men with rising PSA after prostatectomy may be eligible to participate in a new clinical trial at the NIH Clinical Center.

Prostate cancer is one of the most common cancers in men. The prostate is a small gland in the male pelvis that produces and transports seminal fluid. After surgery to remove a cancerous prostate, doctors usually determine if the disease is returning by measuring levels of prostate-specific antigen (PSA) in the patient’s blood. Rising PSA indicates the cancer is returning. Radiation to the pelvis is the standard treatment for prostate cancer that has returned after prostatectomy. The radiation is generally given in low daily doses for 6–7 weeks. In this trial, Deborah Citrin, M.D., of the Radiation Oncology Branch wants to see if giving higher doses of radiation over 2–4 weeks can be as effective at killing cancer cells. The goal is to find the most compressed schedule of radiation that patients can tolerate without strong side effects.

The Center for Cancer Research is NCI’s internal cancer center, a publicly funded organization working to improve the lives of cancer patients by solving important, challenging and neglected problems in cancer research and patient care.  Highly trained physician-scientists develop and carry out clinical trials to create the medicines of tomorrow treating patients at the world’s largest dedicated research hospital on the campus of the National Institutes of Health in Bethesda, Maryland.  For more information on CCR clinical trials click here and click here to subscribe to receive the latest CCR clinical trials news directly to your inbox.

Summary Posted: 02/2018